afternoon's everyone, fiscal Financial our second-quarter Chief Welcome, call. Officer, year Tara Julie. Semb. I to by on call our earnings Thanks, this XXXX am joined
Let provide with growth that a you with drivers respect overview agenda represent of call. and strategy. strategic progress operational today's longer-term of the second-quarter key during to of growth with period. of an the with initiatives our for you the I'll four revenue an I'll performance update start our our recent our components me provide quick Then
discuss results XX% detail review we prepared remarks in fiscal At second-quarter will and representing this which end our earnings updated XXXX then QX greater million, guidance, XXXX, press of with some our total year-over-year. conclude additional today's Tara our call in of release then I'll financial closing thoughts on $X.X afternoon. our the the to we outlook before we questions. open revenue reported growth
technology. reflected for business, driven revenue in growth Advanced performance our by Energy global total QX strong was demand by Our in Renuvion cosmetic our
new the Renuvion improving distributor penetration growth increasing into of adoption the by and from and Advanced o-US business satisfying in of cosmetic increasing a Energy our entering we're our handpieces our demand we As coverage seeing in our distributors; key and US are markets market; focused o-US the driving partnerships. surgery utilization reminder, on generators by and
Our of resulted during to of sales year-over-year. $X.X each items continued respect million, these second increase $X.X XX% the of execution Energy or quarter Advanced an with in million
our We year-over-year. also by growth which saw increased impressive $XXX,XXX OEM or business, in XXX%
growth OEM Symmetry we of and in entered of year sale supply as brand. which generator business contributions and August primarily electrosurgical our from the with divestiture Our Surgical, of was core into agreement the by last driven part Bovie and
Turning performance revenue and $X.X increase Advanced in to Energy by primarily by during increase in XXX% of our XX% a OEM our year-over-year. sales second driven XX% a US sales sales or the our geography, a quarter, US were increased review million by sales.
Energy Advanced of April, events execution tough demand. the in for and overall commend performance, given from in rebounded generators After results the on we the strong quarter. Renuvion growth in pleased to focused utilization-based May We our in the we Our benefited of the quarter. particularly I for distracting staying and very team early June series disruption despite post strong faced quarter. as with in our were sales second well a that as early US growth challenges our
million We the year-over-year. saw increasing sales outside also with growth $X.X or strong international total US XXX%
two growth early international distributors year-over-year. formed second in Our from extent, o-US growth in handpieces our strong to a in which primarily was majority generators we Renuvion that the utilization-related and, distributor the to XXXX, But international modestly very We contributed overwhelming and markets. relationships from of XXXX. our lesser was demand quarter, for growth our driven entered existing countries by new in
Turning our to respect operational with progress an of four to our strategic update initiatives.
and will to Medical initiatives one pursue formalize capabilities us for the sell market. and and safety manufacturing technology. for regulatory procedures. position that four, improving efficiencies. in efficacy enhancing on our Apyx Number for Renuvion our customers. of targeted enable our physician cosmetic you And calls, is to As to prior to I've following shared Renuvion support and new indications Three, surgery the evidence earnings strategic cure market with growth the strategy demonstrating on focused long-term practice commodity specific Two, our we're clinical our clinical four surgery
for Starting and is our US first on in we am that procedure have to have regulatory pleased strategic I with progress. been enable clinical that we're pursuing strategy. US, market the initiative, indications The In our initial market. surgery made cosmetic focused dermal on formalizing the resurfacing, focused report us to will that procedures we Renuvion targeted substantial
March we of application external dermal indication a forward. methodically procedures developing for us quickly engaged resources new to the publicly as for After resurfacing XXX(k) and help submission clinical advise and path to XX, best as XXX(k) withdrawing on committed the our possible, on initial this
XX, Our teams quarter dermal that necessary July on IDE the support new worked feedback protocol are I'm IDE clinical second that we application and trial, we report response our the us for resurfacing during Agency's new and awaiting and develop the prepare materials to a regulatory the new submitted. a diligently currently submitted the secure to and application. to clinical enable we on would pleased
use creation and Agency's feedback resurfacing procedures. and of application a of results Renuvion this new be intended incorporate a the obtain initiate clearance. of for to receive would the clinical the to new support we study expect we The XXX(k) in to evaluate IDE Once approval, trial the dermal
pursuit been resurfacing. new As discussed focus prior clinical dermal our for of on on limited Renuvion not to indications earnings has calls, our
surgery We our would where have market. within potential important needs other address technology indications clinical Renuvion US unmet clinical also we identified believe the cosmetic
begin the happy are the be subdermal To treatment the via will to to laxity that support skin use clinical in announce pursuit this coming intend Renuvion months. We building neck. of our the intend that we indication of the end, indication in pursue for to we of
we this begin July enrolling to Specifically, by and our conduct consisting to profile on very XX obtained that these expect we expect approval am study the December. to feasibility announce safety for in patients to of approximately I XX, patients evaluate of a IDE Renuvion procedures. excited study
In for with new clearance registrations product our by terms to regulatory is our focused large o-US it particularly countries important in surgery and the us Medical those on of is geographic expanding markets. cosmetic growing obtaining own that enter. we this the in that technology strategy, so, regulatory Apyx our year doing In footprint countries, we
During the first Canada Mexico. and quarter, we entered
we this updated we discussed service will into fiscal expectations guidance As material driven extent existing new XXXX be countries To our announce penetrating the calls, utilization-based profile our be accordingly. that them and as assumes contributors prior on we into year, growth will believe that guidance our may countries growth we them by enter demand. incorporate to
reviewer, strategy. our our as of we've the for scientific as a regulatory July, worked Maryland further strategy a planning Dr. Garber master several will tenure she direct as also clearances. Physics the Medical of with worked support FDA made affairs XX We to Lab the Global additions her also over our new months, day-to-day She Regulatory strategy team all recruited pursue recent Director important will of the and Garber Garber Affairs. and clinical In in years to Libet in to submissions. appointed the laboratories. all Medical activities regulatory as Johns XXX University where FDA, review long-term regulatory obtain studies regulatory help capabilities our at FDA, she Dr. Dr. design to an researcher Hopkins Apyx the leading development regulatory we engineer from sites. of and develop bolster In also Applied the part our Prior support and for required and engineering Apyx of electrical as
highlights, member and Worldwide our affairs chairing and Johnson I'm career working spent Regulatory of regulatory eight XX the announce over Committee. Vice Board Miss the President also many division. medical Minnie Regulatory Baylor-Henry Board years and also years XX with Compliance of Medical to Among be in Baylor-Henry, Affairs will her Baylor-Henry device was in of and of newly and FDA. formed over company's Johnson ultimately Directors. newest excited Ms. with a to appointment spent & the for She regulatory promoted joins the affairs, our of years
second Turning strategic initiative. our to
we efficacy the our technology of pursue term, also the second in regulatory during use we're securing procedures. evidence to surgery cosmetic new a in clinical our retrospective to in addition of In has clinical team focused subdermal XXXX. Renuvion our demonstrating to Renuvion on and clinical safety intend studies support strategy, of on expect study of examining near the publish been we half the working liposuction In procedures, which the
you confirmed, Journal yet and access but open Plastic not has with available. once second publicly The sharing study in the Surgery. I we're publication and that additional becomes timing Reconstructive accepted confirmation been looking the am we study of has and the to the quarter, during received recently that manuscript been publication pleased for completed it this submitted forward report to of details
cosmetic to XX, Dr. our four On Edward we Dr. with expertise the of Richard plastic announced Medical Board members Advisory Dr. and Brian Zimmerman. Paul surgery: extensive Dr. Gentile, Ruff, and July Kenney, appointment new in
of With our believe the we established our of to and we to impressive have four Dr. regulatory the of Zamora, evaluate design professionals Duncan new trials addition to our support existing inform clinical consisting Jack including board, these pursuit and advisers Dr. of of an clinical Diane clearances. team strategy,
strategy. our clinical a Larson, development has will support activities Director Kari sites. research experience resources working over our In of clinical years and Senior and of Larson July, Clinical appointed of healthcare Ms. we both develop clinical also and manage Affairs, who the companies XX spent clinical Ms. with longer-term
and affairs MyoScience. Lutronic, aesthetic and has activities managed clinical she research teams clinical companies: medical Importantly, Ulthera, directed developed device and three at
our new customers: our we support third strategic for for make and With prospective customers. to surgeon and in our enhancing respect surgery progress physician practice both continue cosmetic training and support to initiative, developing great
PMPs, US. cases host educational by in by quarter, across sessions key and PMP attended programs, locations performed surgeon our physician These consulting customers During which live mentor continued the surgeons. we the or second were both events potential to include
with surgeons ensure us goal in PMPs that we is directly helping very peers our of across effective the primary to learn country. formal are to ability provide settings. prospective in with and delivering the customers, their proven They've engage training educational from high-quality The
we in efforts, a with of have also sales training charged team team. created our our To clinical specialists supporting small assist
ensuring one our we more one-on-one able technology use new are training surgeon the our and work support pursuing deliver their By clinical of our with allowing of new our encourage the customer cases. first new of sale generators, reps specialists customers to of Renuvion, Following their to on our the while clinical closely Renuvion well-trained to during that of also provide believe business. strong are utilization time our spend specialists
-- to to expand our improving our surgeon we brand. training support Renuvion marketing for addition efforts, pursuing the also In continue
new before-and-after photos. feature we that surgeon During provided marketing the second patient-focused customers to our quarter, brochures
we introduced received first from QX. series We have patient-focused on marketing feedback which also during the positive surgeon customers materials, of Renuvion our
our for lastly, with Board Global Advanced And Laura manufacturing Director to capabilities make Iversen, Energy, in our efficiencies. lean with of and several Operations of is initiative, in input continue connection Swandal. our fourth She and currently new our improving pursuing progress Craig team strategic member, initiatives the her
handpieces. to our Additionally, improve we manufacturing have the of cost identified areas
evident as to We more themselves handpieces. to see continue financial expect our sell these we improvements results in
that to In and fourth laparoscopic regulatory next-generation surgeons upgraded our version procedures addition on feedback XXX(k) I'd were precise strategic J-Plasma to handpiece. to achievement. in of received our version that the congratulate precise an important years, initiative, our respect for them o-US also Cool-Coag In the our interested FDA progress would for feature. that Monday, handpiece J-Plasma we our our an we've laparoscopic recent utilize R&D we with received announced recent teams On market like clearance enable of in to
need a non-contact plasma to called plasma standard that customers Cool-Coag surgeon reminder, to helium a tissue. our wide of energy is our area a beam J-Plasma a This a monopolar coagulate and feature when energy particularly deliver surgeons helpful coagulation, in single addition handpiece. in spray is As feature enables precise to
In response handpiece. to we and demand, surge expertise our development precise to research leveraged in create of this manufacturing J-Plasma in this and our version next-generation
handpiece to XX% for ergonomics. incorporating is lighter than this its next-generation our Cool-Coag improved In addition technology, also predecessor
laparoscopic expect the this of for to offering handpiece pleased and begin procedures, have a by to We're of our quarter. limited launch we surgical enhanced third end
our for variety in Importantly, J-Plasma in surgical European both of the our believe Renuvion many a be and J-Plasma are will market, laparoscopic which precise distributors we the procedures products, handpiece of procedures. sell commercialized used European where
core excellent unfortunate values setback remarks, Stepping with Company's the quarter. under with the difficult journey of circumstances: back, am our leading working together, as prepared energy that talent our for exemplifying initial to the XXX(k) performance my I'm very in end as second going March, opportunities in Company. very incredible cosmetic and dermal I submission an mentioned with the experienced for I our have resurfacing pleased our team the continue done of during we job added of extra at becoming pleased our Despite the earlier the has surgery also for we towards create status quo, challenging the the solutions our team unique to market. mile we our innovator the world's withdrawal new
With Tara year and greater financial XXXX release. detail to over which that, to our let results Tara? turn call our in fiscal me the this financial we updated on afternoon's second-quarter review guidance, discuss
